AstraZeneca AstraZeneca warns German reforms could push pharma launches and investment out of Europe AstraZeneca CEO warns that pharma may avoid launching new medicines in Europe’s largest market
Cypriot presidency EU’s Health Package is Europe’s answer to Trump’s drug pricing policy, says Várhelyi Várhelyi estimated reforms could lower business costs by 20-25 percent - potentially offsetting the impact of US tariffs and "MFN" pricing.
Inside EU Health Inside EU Health: US tariffs and MFN pricing threaten EU investment and access; EMA and FDA agree good AI; ECDC issues warning on Doxy-PEP Inside EU Health: US tariffs and MFN pricing threaten EU investment and access; EMA and FDA agree good AI principles; ECDC issues warning on Doxy-PEP
EU/US Trade US tariffs and MFN pricing threaten pharma investment and access in Europe Rising uncertainty driven by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical companies to delay investment and product launches in Europe
